Multi-Center Study of Natural History in Atypical Parkinsonian Syndromes (MAPS-NH)
This goal of this observational study is to clarify the variations in the natural course of atypical parkinsonian syndromes (APS, including MSA, DLB, PSP, and CBD), such as the progression rate of motor and non-motor symptoms and characteristic imaging evolution patterns. Establish a comprehensive assessment framework for APS, and develop clinical and biological databases to identify biomarkers with early predictive value.
• MSA : Meets the probable MSA criteria in the 2022 Chinese expert consensus on MSA diagnosis (MSA-P or MSA-C subtype); disease duration ≤3 years (from onset of first motor symptoms) .
• DLB : Meets probable DLB criteria per the 2017 McKeith diagnostic criteria; MMSE ≥18 (to exclude severe dementia confounding assessment) .
• PSP : Meets probable PSP-Richardson syndrome criteria per the 2017 PSP diagnostic standards; vertical gaze palsy or postural instability with duration ≤2 years .
• CBD : Meets probable CBD criteria per the 2019 Chinese expert consensus on corticobasal degeneration diagnosis and treatment; asymmetric cortical symptoms (apraxia/dystonia/alien limb).